Optimising Transfusion Support In Critical Illness And Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$262,251.00
Summary
Blood transfusion is commonly used for patient care. Improving our understanding about how to best use blood and blood products and finding ways to reduce the need for transfusion have been identified as important areas of national research. This fellowship aims to investigate interventions to reduce bleeding and the need for transfusion and improve the use of blood transfusion in two patients groups who are major users of blood: critically ill patients and patients with blood cancers.
Pre-hospital Antifibrinolytics For Traumatic Coagulopathy And Haemorrhage (The PATCH Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,668,152.00
Summary
About 2500 Australians die annually from severe injuries. Bleeding is exacerbated by early-onset clotting defects, which are associated with high mortality. The antifibrinolytic agent tranexamic acid has been shown to reduce mortality due to bleeding when given in hospital in less developed trauma systems, but its usefulness as a pre-emptive strike at the scene of injury in developed systems is unknown. Building on our prehospital clinical trials expertise, we will conduct a trial to assess its ....About 2500 Australians die annually from severe injuries. Bleeding is exacerbated by early-onset clotting defects, which are associated with high mortality. The antifibrinolytic agent tranexamic acid has been shown to reduce mortality due to bleeding when given in hospital in less developed trauma systems, but its usefulness as a pre-emptive strike at the scene of injury in developed systems is unknown. Building on our prehospital clinical trials expertise, we will conduct a trial to assess its effect on 6-month death and disability.Read moreRead less
Regulation Of The Haemostatic Activity Of Plasma Von Willebrand Factor
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
Our genes encode proteins that perform the tasks of life. Most proteins are chemically modified after they are made to control how, when, and where they function. Prof Hogg discovered a new chemical modification of proteins that is important in health and disease. He will apply this discovery to develop new diagnostics and therapies for heart attacks and stroke. Prof Hogg is one of the few Australians to take new diagnostics and therapies developed in the lab to evaluation in patients.
STOP-AUST: The Spot Sign And Tranexamic Acid On Preventing Intracerebral Haemorrhage Growth – AUStralasia Trial
Funder
National Health and Medical Research Council
Funding Amount
$764,621.00
Summary
The STOP-AUST study is a randomized controlled trial with the aim of testing whether the medication tranexamic acid when given early within 4.5 hours of symptom onset is superior to standard care alone in stopping intracerebral haemorrhage (ICH, a bleeding into the brain) growth. Total 100 to 150 patients will be enrolled into the study.
Acute Stroke Care: Rapid Unblocking Of Vessels, Mending Ruptures, And Recovery
Funder
National Health and Medical Research Council
Funding Amount
$204,399.00
Summary
During this fellowship, A/Prof Meretoja will 1) use blood biomarkers, telemedicine, and ambulance-based imaging to streamline the time-critical therapy of stroke thrombolysis, 2) run a pharmaceutical trial of the drug tranexamic acid in intracerebral haemorrhage, and 3) use stroke registries in Australia and Finland to disseminate best practices in stroke care pathways.
The rapid interactions of circulating human blood platelets is critical to prevent bleeding, but can cause thrombotic diseases (heart attack, stroke). These highly regulated interactions involve specific adhesive proteins. Our studies will define factors regulating platelet interactions. Imaging the thrombotic process will quantify platelet function at an unprecedented resolution and we have a panel of new candidate reagents that will be assessed for antithrombotic potential.
REDucing Delays In Aneurysmal Subarachnoid Haemorrhage: The REDDISH Study
Funder
National Health and Medical Research Council
Funding Amount
$436,022.00
Summary
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare form of stroke that kills at least 30% of sufferers within 1 month. Outcome can be improved through quickly receiving medical care but many people do not and this likely contributes to the poor outcomes. The REDucing Delays In Subarachnoid Haemorrhage (REDDISH) study will look at cases of aSAH across Tasmanian and Victoria so that we can understand the factors that contribute to delays in treatment and ultimately improve outcomes.